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Niemann-Pick disease type C: mutations 
of NPC1 gene and the course of disease
Ljerka Cvitanović-Šojat1, Maša Malenica1, Monika Kukuruzović1, Tamara Žigman1, 
Kristina Kužnik1, Ana Bielen2
Niemann-Pick disease type C (NP-C) is a rare autosomal recessive disorder caused by mutations in the NPC1 gene in 95% of cases. 
Consequently, unesterifi ed cholesterol accumulates in late endosomes/lysosomes causing extremely varied neurovisceral symptoms. 
For many countries including Croatia, there are no reported NP-C cases to date, mainly because the accurate diagnosis of NP-C 
 requires not easily accessible biochemical and molecular-genetic laboratory tests. Therefore, with the aim to improve clinical prac-
tice and understanding of NP-C in the region, we present the fi rst siblings with NP-C recorded in Croatia. The diagnosis was based on 
histologic, biochemical and genetic tests. Namely, fi lipin staining showed accumulation of unesterifi ed cholesterol and cultured skin 
fi broblasts were defi cient in esterifi cation of exogenously administered cholesterol. Electron microscopy of skin biopsy revealed the 
presence of sequestrated lipids in lysosomes. Molecular analyses showed both siblings to be compound heterozygotes for two 
 disease-causing mutations of NPC1 protein, N1156S and Q922X. Based on comparison with previously reported N1156S homozy-
gotes, we propose that Q922X mutation, causing the formation of a truncated NPC1, has a more severe impact on clinical outcome. 
Further, we observed pronounced diff erences in the disease course in the siblings; i.e. in the boy we observed an earlier onset and a 
much faster neurologic deterioration (late infantile onset), suggesting other genetic and/or environmental factors infl uencing the 
course of the disease. In contrast, the girl exhibited juvenile type of NP-C. In conclusion, when progressive neurologic symptoms 
 develop in late childhood and with a previous history of neonatal cholestasis, the classic late infantile or juvenile type of NP-C must 
be suspected.
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INTRODUCTION
Niemann-Pick disease type C (NP-C, OMIM 257220) is an au-
tosomal recessive lysosomal lipid storage disorder with ex-
tremely heterogeneous clinical representation. NP-C is a 
rare panethnic disease with a minimal calculated incidence 
of 1:150 000 live births. It is caused by mutations in the NPC1 
and/or NPC2 genes (1, 2). Approximately 95% of NP-C cases 
have mutations in the NPC1 gene (MIM 607623; chromo-
some 18q11-q12), encoding a large glycoprotein (1278 
amino acids) with 13 transmembrane domains that resides 
primarily in membrane of late endosomes (LE). The rest of 
patients have mutations in the NPC2 gene (MIM 601015; 
chromosome 14q24.3) encoding a soluble and glycosylated 
protein present in the LE lumen. In healthy individuals, NPC1 
and NPC2 act together as a cellular duo that catalyzes mo-
bilization of cholesterol and its export out of the LEs (1-5). 
Consequently, mutations in one or both genes lead to ac-
cumulation of unesterifi ed cholesterol and glycosphingoli-
pids in late endosomes/lysosomes causing various neuro-
visceral symptoms (1, 6). Today, the NP-C disease variation 
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database lists 252 disease-causing sequence variants of the 
NPC1 gene and 18 of the NPC2 gene (November, 2013) (7). It 
has been shown that mutations correlate with neurologic 
forms of the disease, and nonsense and frameshift muta-
tions are causing the most severe neurologic course (1). NP-
C has extremely heterogeneous clinical presentation, with a 
wide range of symptoms that are not specifi c for the dis-
ease. The age at onset also varies greatly with neonatal, 
early infantile (age at onset 2 months to 2 years), late infan-
tile (2-6 years), juvenile (6-15 years) and adult (>15 years) 
forms. Further, lifespan of patients can be from few days to 
over 60 years of age, with the majority of patients dying be-
tween 10 and 25 years of age. The major systemic symp-
toms include foetal ascites/hydrops, neonatal cholestasis 
and (hepato)splenomegaly. Neurologic symptoms are de-
lay in motor milestones and hypotonia for early infantile 
form of the disease; gait problems, clumsiness, speech de-
lay and cataplexy for late infantile form; school problems, 
ataxia, seizures and cataplexy for juvenile form; and psychi-
atric problems, ataxia, dystonia and dementia for adult form. 
Vertical supranuclear gaze palsy can also appear in all forms 
of the disease (1, 8, 9). After NP-C has been suspected based 
on clinical symptoms, it is necessary to confi rm the diagno-
sis by histologic, biochemical and genetic tests. Due to im-
paired intracellular cholesterol transport in NP-C, esterifi -
cation of exogenously administered cholesterol by cultured 
skin fi broblasts is defi cient at 4.5 or 6 hours. Furthermore, 
fl uorescent fi lipin staining shows accumulation of unesteri-
fi ed cholesterol in lysosomes (1, 8). Electron microscopy 
(EM) of skin biopsy may reveal the presence of sequestrated 
lipids in lysosomes (10). Also, because of prenatal diagnosis 
or identifi cations of carriers in the family, it is advisable to do 
genetic testing (1, 8).
The accurate diagnosis of this rare disease is often a pro-
longed process, with a high probability of misdiagnosis due 
to heterogeneity and non-specifi city of its clinical symp-
toms that arise and progress over varied periods of time (8, 
11). Further, for many countries including Croatia, there are 
no reported NP-C cases to date. Therefore, the aim of this 
paper is to improve clinical practice and understanding of 
NP-C. As an illustration, we present the fi rst cases of NP-C 
disease recorded in Croatia, with emphasis on the impor-
tance of early and accurate diagnosis for the patient and for 
the family.
SUBJECTS AND METHODS
Two siblings, a female born in 1987 and a male born in 1992, 
having juvenile and late infantile form of NP-C, respectively, 
were born after uneventful pregnancy and delivery. Birth 
parameters were normal (body weight, body length, head 
circumference, APGAR). Both had neonatal jaundice, hepat-
osplenomegaly and cholestasis that was resolved in a few 
months following birth. Developmental milestones were 
reached normally, until the onset of the disease.
The girl was 5 years old when hepatosplenomegaly was no-
ticed and had lower interest, concentration and poor draw-
ing abilities. At the age of seven years, before entering 
school, tests were performed and mild intellectual disability 
was shown (reduced school program). Dysrhythmic 
electroencephalogram (EEG) was recorded, while comput-
ed tomography (CT) of the brain and laboratory tests were 
still normal. At the age of nine, the aspartate transaminase 
(AST) level was at the upper limit of the reference range (47 
U/L), without hepatosplenomegaly and with normal other 
liver tests. She did not have a phenotype or laboratory signs 
of hypoplasia/atresia of bile ducts or cholestatic liver dis-
ease. Magnetic resonance (MR) of the brain showed periv-
entricular demyelination, fi rst in frontal and then in occipital 
region, but no cortical atrophy. Leukodystrophy of Pelizae-
us-Merzbacher and white-matter disease were suspected. 
Neurologic symptoms developed, including clumsiness, 
dystonic/athetotic movements, dysmetria, ataxic/spastic 
gait, increased muscle tone and deep tendon refl exes, 
slurred, nasal and poor speech, supported walk, and paresis 
of upward gaze. She had dysrhythmic EEG; dyssynchrony of 
visual evoked potentials (VEP). Brain stem evoked response 
audiometry (BERA), electromyoneurography (EMNG), cere-
brospinal fl uid (CSF) and skin biopsy by EM were normal. 
Mitochondrial, peroxisomal and Wilson diseases were ex-
cluded based on laboratory testing. Catalytic activities of β-
hexosaminidase A and A and B (βHEX A A&B), β-galactosi-
dase (βGAL), β-glucosidase (βGLUC) and arylsulfatase A 
(ARILSA) were within the reference values. Grand mal sei-
zure in duration of 5 minutes occurred at the age of 9 years 
and 9 months. Therapy with valproic acid, carbamazepine 
and phenobarbital was started. At the time, NP-C was sus-
pected and the second skin biopsy revealed lipid inclusions 
in dermal axons leading to the diagnosis. The diagnosis of 
NP-C was confi rmed in cultured fi broblasts by fi lipin test 
and very low esterifi cation of exogenously administered 
cholesterol. Therapy included low cholesterol diet, lovasta-
tin, cholestyramine and niacin. At the age of 10 years and 5 
months, the clinical picture was progressively deteriorating, 
with brain MR showing not only demyelination but also 
cortical atrophy. Intractable epilepsy developed. Therapy 
with vigabatrin and neurontin was introduced, low choles-
terol diet was stopped. When she was 11 years old, she was 
in vegetative state and percutaneous endoscopic gastros-
tomy (PEG) had to be applied with supportive measures 
and palliative care. She also had insomnia. She died when 
she was 11 years and 10 months old. Autopsy revealed bal-
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looning of neuronal cytoplasm and lipid laden foam cells in 
the spleen, liver, lymph nodes and bone marrow.
The male sibling had earlier onset and faster progress of the 
disease (Figure 1). At the time he was born, his elder sister 
had not yet been correctly diagnosed as NP-C. After birth, 
he had neonatal jaundice, hepatosplenomegaly and 
cholestasis that was resolved in a few months following 
birth. When the boy was 1.5 year old, he fell from 3-m height 
and sustained head trauma and leg fracture. In his early 
childhood, he suff ered frequent viral infections. Despite 
normal early development, the fi rst symptoms of NP-C ap-
peared as very slow speech development (2-3 words at 3.5 
years). At the age of 4 years, behavioral and cognitive prob-
lems appeared, such as hyperactivity, poor memory and 
slurred speech. Logotherapy was started. He had hepat-
osplenomegaly, AST 44 U/L and bile acid 10 mmol/L. Other 
liver tests were normal and there were no phenotype/labo-
ratory signs for hypoplasia/atresia of bile ducts and choles-
tatic liver disease. Skin biopsy was done when the boy was 
5 years and 8 months old. In contrast to the results of his 
sister’s skin biopsy, no lipid inclusions were found. Never-
theless, in fi broblasts fi lipin test was positive and exoge-
nously administered cholesterol esterifi cation defective, 
leading to the diagnosis of NP-C. Although EEG, VEP and 
laboratory tests were normal at the time, IQ was 86, and MR 
revealed demyelination in the occipital part of the brain. 
Therapy with lovastatin, cholestyramine, niacin and low-
cholesterol diet was administered. At the age of 6 years, 
epilepsy fi ts started, EEG was dysrhythmic, dysarthria and 
ataxia appeared. He was enrolled in the school for children 
with special needs (mild intellectual disability). Car-
bamazepine and vigabatrin were added to therapy, while 
cholesterol-lowering therapy was stopped since there was 
no evidence for amelioration of neurologic symptoms. He 
died when he was 10 years and 3 months old.
Molecular analysis at fi rst excluded the most prevalent NP-C 
causing I1061T mutation (12) (by courtesy of M.T. Vanier) 
and after the deaths it was found that both siblings were 
compound heterozygotes for two disease-causing muta-
tions in the NPC1 gene (courtesy of S. Calandra). NPC1 allele 
with A3467G mutation in exon 22 codes for defective pro-
tein with the amino acid serine instead of asparagine at po-
sition 156 (N1156S), while C2764T in exon 18 causes non-
sense mutation, i.e. conversion of the amino acid glutamine 
into a stop codon (Q922X). The probands’ mother was het-
erozygous for Q922X mutation and probands’ father was 
heterozygous for N1156S mutation.
DISCUSSION AND CONCLUSIONS
Niemann-Pick disease type C is a rare panethnic disease, but 
data on disease-causing mutations were collected mostly 
in Western Europe and the USA (7). This has led us to present 
the fi rst case of siblings with NP-C in Croatia with the aim to 
improve clinical practice and understanding of NP-C in the 
region.
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Molecular analyses showed that both siblings were com-
pound heterozygotes for two disease-causing mutations in 
the NPC1 gene, leading to the production of defective NPC1 
protein variants with N1156S and Q922X mutations. The 
N1156S mutation is positioned within the luminal portion 
of NPC1, between the 10th and 11th transmembrane domain. 
It seems that this allele has a considerably wide distribution 
because, besides the cases presented here, it has been 
found in several patients from Spain (13), United Kingdom 
(14), Israel (15) and elsewhere (16). Only the Israeli patient 
was homozygous and therefore off ered an opportunity to 
study the eff ect of this particular mutation on the pheno-
type. This patient had juvenile onset of symptoms (hepat-
osplenomegaly at 4 months), but otherwise showed mod-
erate clinical phenotype in comparison to our siblings. 
Therefore, we presume that in the case of siblings presented 
here, Q922X mutation (17), causing the formation of a trun-
cated NPC 1 protein of 921 amino acids, had a more severe 
impact on the clinical outcome than N1156S mutation. Cor-
relation of nonsense mutations of NPC1 and early neuro-
logic onset and shorter life span was suggested earlier (18). 
Interestingly, this mutation was found only in genomic DNA, 
while in associated cDNA it was not detectable (data not 
shown). This raises the possibility of degradation of mRNA 
containing premature stop codon (17). In the analyzed fam-
ily, direct consanguinity was not detected, but both parents 
trace their origin from the island of Krk: maternal grandpar-
ents have second cousins from the village of Linardići (Krk), 
while paternal grandfather is from Punat (Krk). It is well 
known that some villages on the island of Krk present small, 
isolated and highly inbred populations, therefore with a 
high chance of unusually high frequencies of otherwise rare 
genetic variants (e.g., hereditary dwarfi sm) (19).
Although both siblings were of the same NPC1 genotype, 
phenotypic diff erences could be observed (Figure 1). As de-
scribed in more detail above, in the neonatal and early in-
fantile period both siblings had transient jaundice and 
hepatosplenomegaly. In the girl, symptoms appeared on 
the 20th day of life and lasted for 3 months, and the boy had 
symptoms from the birth, the symptoms were more pro-
nounced and lasted for 6 months. Afterwards, both siblings 
had normal developmental milestones. At the age of 5 
years, a loss of interest and concentration with poor draw-
ing was noticed in the girl. In comparison, the boy exhibited 
behavioral problems, hyperactivity, poor memory and 
slurred speech at the age of 4 years. At the age of 7 years, 
the girl had dysrhythmic EEG, normal CT of the brain and 
because of borderline intellectual disability she was admit-
ted to the regular school with reduced school program. The 
boy had 6.5 years of age, dysarthria and ataxia were ob-
served, and he was admitted to the school for children with 
special needs because of mild intellectual disability. When 
the girl was 9 years old, there was no hepatosplenomegaly 
and there were no laboratory signs of hypoplasia or atresia 
of bile ducts or cholestatic liver disease. At the same time, 
gastroenterological examination performed in the boy at 
the age of 4 years showed mild hepatosplenomegaly, but 
no laboratory signs of liver disease. The girl learned to write 
and read, but at the age of 9 years and 4 months she stopped 
to go to school because of dystonia, athetosis, dysmetria, 
ataxia, spastic gait, slurred nasal and poor speech, and MR of 
the brain showed high signal in the periventricular occipital 
region. Extensive neuropediatric workup was done and re-
sults were normal including EM skin biopsy, only some 
changes were seen on EEG and VEP. Because of the progres-
sion of demyelination in the frontal and occipital part and 
because of the fi rst grand mal attack at the age of 9 years 
and 9 months, paresis of upward gaze and deterioration of 
motor skills, skin biopsy was repeated and lipid inclusions in 
dermal axons were found suggesting the diagnosis of NP-C. 
The boy had his fi rst epileptic fi t at a younger age (6 years), 
the fi rst MR of the brain at the age of 7 years showing demy-
elination in the occipital part; EEG, VEP and EM skin biopsy 
showed normal results. When the girl had 10 years and 5 
months and the boy 5 years and 8 months, NP-C was con-
fi rmed by assaying cultured fi broblasts for cholesterol es-
terifi cation and staining for unesterifi ed cholesterol with fi li-
pin. At 10 years and 10 months, the girl had progression of 
demyelination with cortical atrophy, progressive deteriora-
tion with intractable epilepsy. At the age of 11 years, the girl 
was in vegetative state with insomnia, received PEG and 
died at 11 years and 10 months having permanent epileptic 
attacks despite antiepileptic polytherapy. The boy went to 
special school for two years and was not able to write and 
read. He had frequent epileptic attacks, dysarthria, ataxia, 
athetosis, spastic gait, slurred nasal and poor speech, fol-
lowed by deterioration and death at the age of 10 years and 
3 months. The parents had a third child, a healthy boy later 
diagnosed as heterozygous for the Gln922X mutation.
The studies of families with NP-C have shown that the af-
fected siblings present a similar clinical course (1, 20). How-
ever, diff erences between siblings bearing the same alleles 
are also described, e.g., patients with the perinatal form can 
have siblings with infantile- or juvenile-onset neurologic 
disease (9, 14, 21). As described here, in the boy we ob-
served an earlier onset and a much faster neurologic dete-
rioration (late infantile NP-C), suggesting other genetic and/
or environmental factors infl uencing the course of the dis-
ease. In contrast, the girl exhibited juvenile type of NP-C.
Due to the heterogeneous symptoms and age at onset, NP-
C is often misdiagnosed (8, 11). Even when clinical tests ex-
clude other diseases, confi rmation of NP-C requires further 
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biochemical and molecular-genetic laboratory tests. In the 
cases presented here, the diagnosis of NP-C in siblings was 
hampered by rarity of the disease leading to insuffi  cient 
clinical awareness, as well as nonexistence of the required 
laboratory testing in Croatia. Therefore, with the extreme 
commitment of physicians and family, necessary tests were 
conducted in the University Medical Center, New York (skin 
biopsy for determination of lipid inclusions in dermal axons, 
E.H. Kolodny), Institut National de la Santé et de la Recher-
che Médicale, Lyon (fi lipin test and cholesterol esterifi cation 
in fi broblasts, M.T. Vanier) and Dipartimento di Scienze Bio-
mediche, Metaboliche e Neuroscienze Modena (molecular 
genetic analyses, S. Calandra). It has to be noted that both 
biochemical tests in fi broblasts are necessary for accurate 
NP-C diagnosis, since reliance on one or the other may lead 
to the diagnosis being missed in some cases: the transport 
of cholesterol is studied by cholesterol esterifi cation studies 
and the storage of cholesterol is assessed by staining the 
cells with fi lipin, which glows under ultraviolet light (8, 21). 
Skin biopsy of dermal axons was positive for lipid inclusions 
only in the female sibling. Therefore, this test has to be taken 
with caution. The diagnosis should be confi rmed in sus-
pected cases by genetic testing (i.e. DNA sequencing) (9).
At the time of the study, there was no disease-modifying 
therapy available for NP-C (8). Therefore, therapy was limited 
to supportive measures, including pharmacotherapy to al-
leviate neurologic symptoms, such as antiepileptic drugs. At 
the time, a combination of hypocholesterolemic drugs and 
low-cholesterol diet was suggested to alleviate the symp-
toms, but no amelioration of the neurologic disease was 
observed in the presented case, or in the literature (22). It 
was recently shown that miglustat (N-butyldeoxynojirimy-
cin; NB-DNJ; Zavesca®, Actelion Pharmaceuticals Ltd.) delays 
the onset of neurologic symptoms. This molecule acts as an 
inhibitor of glucosylceramide synthase, which glucosylates 
ceramide to form glucosylceramide, the fi rst step in the syn-
thesis of glycosphingolipids (9). Miglustat has the ability to 
cross the blood-brain barrier and to prolong survival in ani-
mal models of NP-C (23, 24). Today, the European Union has 
extended the indication of miglustat to the treatment of 
progressive neurologic manifestations in adult and paediat-
ric patients with NP-C, and the drug is now approved for 
this indication in several other countries as the fi rst specifi c 
treatment for NP-C that can slow down or stop the progres-
sion of neurologic symptoms (1, 8, 9). The approval of miglu-
stat was based on data from several studies that showed 
stabilization of the neurologic disease course in patients 
treated for one year or more (25-28). Regarding the cases 
presented here, the female sibling did not receive miglustat 
because at the time it was still under investigation and she 
was deteriorated and in vegetative state. Following insuffi  -
cient information about the pharmacokinetics, effi  cacy and 
safety in NP-C patients, the male sibling did not enter clini-
cal trial in 2000.
In conclusion, in late childhood when progressive neurologic 
symptoms develop and with a previous history of neonatal 
cholestasis without known aetiology, a classic late infantile or 
juvenile type of NP-C must be suspected. A timely and accu-
rate diagnosis is important because now it allows not only 
support and palliative care but also early miglustat therapy, as 
well as appropriate family counselling.
ACKNOWLEDGMENTS
The authors would like to thank M.T. Vanier, S. Calandra, E. 
Kolodny, P.G. Penchev, M.C. Patterson, J.E. Wraith, J. Imrie, B. 
Bambi, The Ara Parseghian Medical Research Foundation 
and Niemann Pick Disease Group UK for help with cytologic, 
biochemical and molecular biology testing of the patients 
and parents and for the support.
Abbreviations:
NP-C - Niemann-Pick disease type C
EEG - electroencephalogram
CT - computed tomography
AST - aspartate transaminase
MR - magnetic resonance
VEP - visual evoked potentials
BERA - brain stem evoked response audiometry
EMNG - electromyoneurography
CSF - cerebrospinal fl uid









DOPRINOSI AUTORA/DECLARATION OF AUTHORSHIP
Svi autori jednako su doprinijeli izradi rada/All authors have equally contrib-
uted to a manuscript writing
SUKOB INTERESA/CONFLICT OF INTEREST
Autori su popunili the Unifi ed Competing Interest form na www.icmje.org/
coi_disclosure.pdf (dostupno na zahtjev) obrazac i izjavljuju: nemaju potporu 
niti jedne organizacije za objavljeni rad; nemaju fi nancijsku potporu niti 
jedne organizacije koja bi mogla imati interes za objavu ovog rada u po-
sljednje 3 godine; nemaju drugih veza ili aktivnosti koje bi mogle utjecati 
na objavljeni rad./All authors have completed the Unifi ed Competing Interest 
form at www.icmje.org/coi_disclosure.pdf (available on request from the cor-
responding author) and declare: no support from any organization for the sub-
mitted work; no fi nancial relationships with any organizations that might have 
260
CVITANOVIĆ-ŠOJAT LJ ET AL. NIEMANN-PICK DISEASE TYPE C. PAEDIATR CROAT. 2014;58:255-61
an interest in the submitted work in the previous 3 years; no other relationships 
or activities that could appear to have infl uenced the submitted work. 
REFERENCES
 1.  Vanier M. Niemann-Pick disease type C. Orphanet J Rare Dis. 2010;5:1-18. 
http://dx.doi.org/10.1186/1750-1172-5-16
 2.  Vanier MT, Millat G. Niemann-Pick disease type C. Clin Genet. 2003;64:269-81. 
http://dx.doi.org/10.1034/j.1399-0004.2003.00147.x
 3.  Infante RE, Wang ML, Radhakrishnan A, Kwon HJ, Brown MS, Goldstein JL. 
NPC2 facilitates bidirectional transfer of cholesterol between NPC1 and 
lipid bilayers, a step in cholesterol egress from lysosomes. Proc Natl Acad 
Sci U S A. 2008;105:15287-92. 
http://dx.doi.org/10.1073/pnas.0807328105
 4.  Subramanian K, Balch WE. NPC1/NPC2 function as a tag team duo 
to mobilize cholesterol. Proc Natl Acad Sci U S A. 2008;105:15223-4. 
http://dx.doi.org/10.1073/pnas.0808256105
 5.  Sleat DE, Wiseman JA, El-Banna M et al. Genetic evidence for nonredundant 
functional cooperativity between NPC1 and NPC2 in lipid transport. 
Proc Natl Acad Sci U S A. 2004;101:5886-91. 
http://dx.doi.org/10.1073/pnas.0308456101
 6.  Rosenbaum AI, Maxfi eld FR. Niemann-Pick type C disease: molecular 
mechanisms and potential therapeutic approaches. J Neurochem. 
2011;116:789-95. 
http://dx.doi.org/10.1111/j.1471-4159.2010.06976.x
 7.  Runz H, Dolle D, Schlitter AM, Zschocke J. NPC-db, a Niemann-Pick type C 
disease gene variation database. Hum Mutat. 2008;29:345-50. 
http://dx.doi.org/10.1002/humu.20636
 8.  Wraith JE, Baumgartner MR, Bembi B et al. Recommendations on the 
diagnosis and management of Niemann-Pick disease type C. Mol Genet 
Metab. 2009;98:152-65. 
http://dx.doi.org/10.1016/j.ymgme.2009.06.008
 9.  Patterson MC, Hendriksz CJ, Walterfang M, Sedel F, Vanier MT, Wijburg F. 
Recommendations for the diagnosis and management of Niemann–Pick 
disease type C: An update. Mol Genet Metab. 2012;106:330-44. 
http://dx.doi.org/10.1016/j.ymgme.2012.03.012
10.  Boustany RMN, Kaye E, Alroy J. Ultrastructural fi ndings in skin from patients 
with Niemann-Pick disease, type C. Pediatr Neurol. 1990;6:177-83. 
http://dx.doi.org/10.1016/0887-8994(90)90059-A
11.  Lo SM, McNamara J, Seashore MR, Mistry PK. Misdiagnosis 
of Niemann-Pick disease type C as Gaucher disease. J Inherit Metab Dis. 
2010;33 (Suppl 3):429-33. 
http://dx.doi.org/10.1007/s10545-010-9214-3
12.  Park WD, O’Brien JF, Lundquist PA et al. Identifi cation of 58 novel 
mutations in Niemann-Pick disease type C: Correlation with biochemical 
phenotype and importance of PTC1-like domains in NPC1. Hum Mutat. 
2003;22:313-25. http://dx.doi.org/10.1002/humu.10255
13.  Fernandez-Valero EM, Ballart A, Iturriaga C et al. Identifi cation 
of 25 new mutations in 40 unrelated Spanish Niemann-Pick type C 
patients: genotype-phenotype correlations. Clin Genet. 2005;68:245-54. 
http://dx.doi.org/10.1111/j.1399-0004.2005.00490.x
14.  Imrie J, Dasgupta S, Besley GT et al. The natural history of Niemann-Pick 
disease type C in the UK. J Inherit Metab Dis. 2007;30:51-9. 
http://dx.doi.org/10.1007/s10545-006-0384-7
15.  Meiner V, Shpitzen S, Mandel H et al. Clinical-biochemical correlation 
in molecularly characterized patients with Niemann-Pick type C. Genet 
Med. 2001;3:343-8. 
http://dx.doi.org/10.1097/00125817-200109000-00003
16.  Sun X, Marks DL, Park WD et al. Niemann-Pick C variant detection by 
altered sphingolipid traffi  cking and correlation with mutations within 
a specifi c domain of NPC1. Am J Hum Genet. 2001;68:1361-72. 
http://dx.doi.org/10.1086/320599
17.  Tarugi P, Ballarini G, Bembi B et al. Niemann-Pick type C disease. J Lipid Res. 
2002;43:1908-19. 
http://dx.doi.org/10.1194/jlr.M200203-JLR200
18.  Millat G, Marçais C, Tomasetto C et al. Niemann-Pick C1 disease: 
Correlations between NPC1 mutations, levels of NPC1 protein, and 
phenotypes emphasize the functional signifi cance of the putative sterol-
sensing domain and of the cysteine-rich luminal loop. Am J Hum Genet. 
2001;68:1373-85. 
http://dx.doi.org/10.1086/320606
19.  Krzisnik C, Kolacio Z, Battelino T, Brown M, Parks JS, Laron Z. The “Little 
People” of the island of Krk-revisited. Etiology of hypopituitarism revealed. 
Int J Disabil Hum Dev. 1999;1:9-20. 
http://dx.doi.org/10.1515/IJDHD.1999.1.1.9
20.  Yatziv S, Gershon Z, Ornoy A, Bach G. Clinical heterogeneity in a sibship 
with Niemann-Pick disease type C. Clin Genet. 1983;23:125-31. 
http://dx.doi.org/10.1111/j.1399-0004.1983.tb01860.x
21.  Vanier MT, Wenger DA, Comly ME, Rousson R, Brady RO, Pentchev PG. 
Niemann-Pick disease group C: clinical variability and diagnosis based 
on defective cholesterol esterifi cation: A collaborative study on 70 patients. 
Clin Genet. 1988;33:331-48. 
http://dx.doi.org/10.1111/j.1399-0004.1988.tb03460.x
22.  Schiff mann R. Niemann-Pick disease type C. JAMA. 1996;276:561-4. 
http://dx.doi.org/10.1001/jama.1996.03540070057031
23.  Treiber A, Morand O, Clozel M. The pharmacokinetics and tissue 
distribution of the glucosylceramide synthase inhibitor miglustat in the rat. 
Xenobiotica. 2007;37:298-314. 
http://dx.doi.org/10.1080/00498250601094543
24.  Zervas M, Somers KL, Thrall MA, Walkley SU. Critical role for 
glycosphingolipids in Niemann-Pick disease type C. Curr Biol. 
2001;11:1283-7. 
http://dx.doi.org/10.1016/S0960-9822(01)00396-7
25.  Patterson MC, Vecchio D, Jacklin E et al. Long-term miglustat therapy in 
children with Niemann-Pick disease type C. J Child Neurol. 2010;25:300-5. 
http://dx.doi.org/10.1177/0883073809344222
26.  Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE. Miglustat for treatment 
of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol. 
2007;6:765-72. 
http://dx.doi.org/10.1016/S1474-4422(07)70194-1
27.  Pineda M, Wraith J, Mengel E et al. Miglustat in patients with Niemann-Pick 
disease Type C (NP-C): a multicenter observational retrospective cohort 
study. Mol Genet Metab. 2009;98:243-9. 
http://dx.doi.org/10.1016/j.ymgme.2009.07.003
28.  Wraith JE, Vecchio D, Jacklin E et al. Miglustat in adult and juvenile patients 
with Niemann–Pick disease type C: long-term data from a clinical trial. 
Mol Genet Metab. 2010;99:351-7. 
http://dx.doi.org/10.1016/j.ymgme.2009.12.006
261
PAEDIATR CROAT. 2014;58:255-61 CVITANOVIĆ-ŠOJAT LJ ET AL. NIEMANN-PICK DISEASE TYPE C.
S A Ž E T A K
Niemann-Pickova bolest tip C: mutacije gena NPC1 
i tijek bolesti
Lj. Cvitanović-Šojat, M. Malenica, M. Kukuruzović, T. Žigman, K. Kužnik, A. Bielen
Niemann-Pickova bolest tip C rijedak je autosomni recesivni poremećaj, u 95% slučajeva uzrokovan mutacijama gena NPC1. Kao 
posljedica mutacija dolazi do nakupljanja neesterifi ciranog kolesterola u kasnim endosomima/lizosomima, što uzrokuje vrlo razno-
like neurovisceralne simptome. U mnogim zemljama, uključujući Hrvatsku, do danas nema opisanih slučajeva ove bolesti, uglav-
nom zbog toga što su za postavljanje točne dijagnoze potrebne teško dostupne biokemijske i molekularno-biološke laboratorijske 
pretrage. Stoga radi poboljšanja kliničke prakse i razumijevanja ove bolesti u regiji, opisujemo prvi slučaj brata i sestre oboljelih od 
NP-C-a za Hrvatsku. Dijagnoza se temeljila na histološkim, biokemijskim i genetičkim pretragama. Nakupljanje neesterifi ciranog 
kolesterola dokazano je „Filipin” bojenjem, a nedostatna esterifi kacija izvana unijetog kolesterola dokazana je u kulturi fi broblasta. 
Elektronskom mikroskopijom biopsije kože dokazane su nakupine lipida u lizosomima. Molekularna analiza je pokazala da su brat 
i sestra heterozigoti, nositelji dviju mutacija gena NPC1, te je predviđeno da proteini NPC1 nose mutacije N1156S i Q922X. Temeljem 
usporedbe s podatcima iz literature o N1156S homozigotima, pretpostavljeno je da je mutacija Q922X, koja uzrokuje preuranjeni 
završetak translacije proteina NPC1, značajnije utječu na kliničku sliku. Uz to su razlike u tijeku bolesti kod dječaka i djevojčice bile vrlo 
izražene. Kod dječaka su se prvi simptomi pojavili mnogo ranije i došlo je do bržeg neurološkog propadanja (kasni infantilni tip 
 bolesti), vjerojatno zbog utjecaja drugih genetskih i/ili okolišnih čimbenika na tijek bolesti. Nasuprot tome, djevojčica je imala 
 juvenilni tip bolesti. Zaključno, ako se nakon zabilježene neonatalne kolestaze u kasnom djetinjstvu pojave progresivni neurološki 
simptomi, treba posumnjati na klasični kasni infantilni ili juvenilni tip NP-C-a.
Ključne riječi: Niemann-Pickova bolest, tip C; blizanci; NPC1 protein, humani
